{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-023753","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.541135+00:00","generated_at":"2026-06-14T16:07:04.498934+00:00","sec_items":["1.01","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pyxis Oncology acquires Apexigen in ~$16M all-stock deal; CMO resigns","bullets":["Merger valued at ~$16M enterprise value; implied $0.64 per Apexigen share; exchange ratio 0.1725 PYXS shares per APGN share.","Pyxis stockholders to own ~90% of combined company; Apexigen stockholders ~10%; deal expected to close mid-2023.","Adds klinical-stage CD40 agonist sotigalimab (Phase 2) and APXiMAB antibody platform to Pyxis' FACT ADC toolkit.","Cash runway extended into first half of 2025 per company guidance.","CMO Jay Feingold steps down effective June 15, 2023; will serve as advisor until successor is named."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-023753","json":"https://secwatch.observer/filing/0000950170-23-023753.json","markdown":"https://secwatch.observer/filing/0000950170-23-023753.md","text":"https://secwatch.observer/filing/0000950170-23-023753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/0000950170-23-023753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/pyxs-20230523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T16:07:04.498934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49ee5e14ed","claim":"Jay Feingold resigned as Chief Medical Officer at Pyxis Oncology, Inc..","evidence_excerpt":"On May 24, 2023, the Company announced that Jay Feingold, M.D., Ph.D., will be stepping down from his position as the Company's Chief Medical Officer to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/0000950170-23-023753-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"6048deed61b76258c170cae056071615dbd69cf0","claim":"Pyxis Oncology, Inc. entered into Merger Agreement with Apexigen, Inc. (effective 2023-05-23).","evidence_excerpt":"On May 23, 2023, Pyxis Oncology, Inc., a Delaware corporation (“Pyxis Oncology” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Ascent Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Apexigen, Inc., a Delaware corporation (“Apexigen”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023023753/0000950170-23-023753-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Apexigen, Inc."},{"label":"Effective","value":"2023-05-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}